Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 11
Submit an article Journal homepage
3,654
Views
4
CrossRef citations to date
0
Altmetric
Neurology

Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses

Imtiaz A. Samjooa EVERSANA, Burlington, CanadaORCID Iconhttps://orcid.org/0000-0003-1415-8055
ORCID Icon,
Evelyn Worthingtona EVERSANA, Burlington, CanadaORCID Iconhttps://orcid.org/0000-0003-1659-2082
ORCID Icon,
Anja Haltnerb EVERSANA, Sydney, CanadaORCID Iconhttps://orcid.org/0000-0002-9829-7791
ORCID Icon,
Paul Spinb EVERSANA, Sydney, CanadaORCID Iconhttps://orcid.org/0000-0002-4622-3547
ORCID Icon,
Christopher Drudgea EVERSANA, Burlington, CanadaORCID Iconhttps://orcid.org/0000-0001-9721-3069
ORCID Icon,
Chris Cameronb EVERSANA, Sydney, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3613-760X
ORCID Icon,
Róisín Brennanc Novartis Ireland, Dublin, Ireland
,
Frank Dahlked Novartis Pharma AG, Basel, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-3333-6291
ORCID Icon &
Nicholas Adlardd Novartis Pharma AG, Basel, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-6912-1685
ORCID Icon show all
Pages 1933-1944 | Received 06 Jul 2021, Accepted 11 Aug 2021, Published online: 26 Aug 2021

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Christopher Drudge, Imtiaz A Samjoo, Róisín Brennan, Lohit Badgujar, Vivek Khurana, Santosh Tiwari, Nicholas Adlard & Judit Banhazi. (2023) An overview of reviews with network meta-analyses comparing disease-modifying therapies for relapsing multiple sclerosis. Future Neurology 18:3.
Read now
Sajida Sabsabi, Elio Mikhael, Georges Jalkh, Gabrielle Macaron & Mary Rensel. (2022) Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Preference and Adherence 16, pages 1307-1319.
Read now
Victor Constantinescu, Katja Akgün & Tjalf Ziemssen. (2022) Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more. Expert Opinion on Drug Metabolism & Toxicology 18:10, pages 675-693.
Read now

Articles from other publishers (1)

Martin Vališ, Anat Achiron, Hans Peter Hartung, Jan Mareš, Veronika Tichá, Pavel Štourač, Simona Halusková, Francesco Angelucci & Zbyšek Pavelek. (2023) The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis. Drugs in R&D 23:4, pages 331-338.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.